Compare Stocks: PTCT, UTHR, MRNA, and INSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$132.55 +33.9%	$104.66	$90.39 ▼ $212.75	$21.46B	0.81	2.63 million shs	12.03 million shs
MRNA Moderna	$53.86 -4.3%	$60.04	$22.28 ▼ $85.60	$22.46B	0.91	5.26 million shs	5.59 million shs
PTCT PTC Therapeutics	$70.85 +2.4%	$77.55	$43.17 ▼ $90.87	$5.78B	0.56	1.36 million shs	928,897 shs
UTHR United Therapeutics	$532.94 +2.7%	$539.78	$292.34 ▼ $609.35	$22.03B	0.59	426,933 shs	992,958 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	+33.86%	+30.60%	+17.47%	+31.01%	+19.14%
MRNA Moderna	-4.27%	-7.01%	-32.48%	-0.90%	+101.65%
PTCT PTC Therapeutics	+2.37%	-6.18%	-20.57%	-3.85%	+37.95%
UTHR United Therapeutics	+2.62%	+1.35%	-5.46%	-5.66%	+76.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$132.55 +33.9%	$104.66	$90.39 ▼ $212.75	$21.46B	0.81	2.63 million shs	12.03 million shs
MRNA Moderna	$53.86 -4.3%	$60.04	$22.28 ▼ $85.60	$22.46B	0.91	5.26 million shs	5.59 million shs
PTCT PTC Therapeutics	$70.85 +2.4%	$77.55	$43.17 ▼ $90.87	$5.78B	0.56	1.36 million shs	928,897 shs
UTHR United Therapeutics	$532.94 +2.7%	$539.78	$292.34 ▼ $609.35	$22.03B	0.59	426,933 shs	992,958 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	+33.86%	+30.60%	+17.47%	+31.01%	+19.14%
MRNA Moderna	-4.27%	-7.01%	-32.48%	-0.90%	+101.65%
PTCT PTC Therapeutics	+2.37%	-6.18%	-20.57%	-3.85%	+37.95%
UTHR United Therapeutics	+2.62%	+1.35%	-5.46%	-5.66%	+76.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSM Insmed	3.00	Buy	$207.04	56.20% Upside
MRNA Moderna	1.88	Reduce	$42.13	-21.77% Downside
PTCT PTC Therapeutics	2.79	Moderate Buy	$95.75	35.14% Upside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	21.21% Upside

Current Analyst Ratings Breakdown

Latest PTCT, UTHR, MRNA, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$175.00
8/6/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$515.00
8/6/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$704.00 ➝ $677.00
8/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$41.00 ➝ $60.00
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
7/31/2026	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $104.00
7/31/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $106.00
7/28/2026	INSM Insmed	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$235.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSM Insmed	$819.56M	35.06	N/A	N/A	$3.46 per share	38.31
MRNA Moderna	$1.94B	11.06	N/A	N/A	$16.93 per share	3.18
PTCT PTC Therapeutics	$1.73B	3.42	$8.98 per share	7.89	($1.98) per share	-35.78
UTHR United Therapeutics	$3.18B	7.11	$33.88 per share	15.73	$150.78 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSM Insmed	-$1.28B	-$5.75	N/A	232.54	N/A	-144.44%	-130.11%	-51.57%	N/A
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	N/A
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	31.91	1.92	-3.80%	-362.45%	-1.32%	N/A
UTHR United Therapeutics	$1.33B	$27.09	19.07	16.88	1.74	41.56%	20.18%	17.98%	N/A

Latest PTCT, UTHR, MRNA, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$393.74 million	$425.49 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
5/7/2026	Q1 2026	INSM Insmed	-$0.90	-$0.76	+$0.14	-$0.76	$300.81 million	$305.96 million
5/7/2026	Q1 2026	PTCT PTC Therapeutics	-$0.45	-$0.03	+$0.42	-$0.03	$217.42 million	$272.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSM Insmed	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSM Insmed	0.80	4.47	4.10
MRNA Moderna	0.09	2.29	2.18
PTCT PTC Therapeutics	N/A	3.39	3.28
UTHR United Therapeutics	N/A	4.64	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSM Insmed	N/A
MRNA Moderna	75.33%
PTCT PTC Therapeutics	N/A
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
INSM Insmed	2.10%
MRNA Moderna	10.80%
PTCT PTC Therapeutics	5.30%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSM Insmed	1,664	216.75 million	212.20 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
UTHR United Therapeutics	1,400	42.45 million	38.80 million	Optionable

PTCT, UTHR, MRNA, and INSM Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

1 hour ago | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,902,570.00 in Stock

3 hours ago | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE

4 hours ago | marketbeat.com

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

August 6 at 7:59 PM | finance.yahoo.com

Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 6 at 5:06 PM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 6 at 5:06 PM | marketbeat.com

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

August 6 at 3:10 PM | tipranks.com

UTHR Q2 2026 deep dive: Product pipeline developments offset competitive pressures

August 6 at 2:58 PM | msn.com

Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

August 6 at 2:17 PM | marketbeat.com

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

August 6 at 10:05 AM | zacks.com

United Therapeutics Balances Tyvaso Woes With Pipeline Wins

August 5 at 8:11 PM | tipranks.com

United Therapeutics Q2 Earnings Call Highlights

August 5 at 4:03 PM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Announces Earnings Results

August 5 at 2:10 PM | marketbeat.com

United Therapeutics Q2 Net Income Rises, Revenue Falls

August 5 at 1:22 PM | finance.yahoo.com

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

August 5 at 1:00 PM | seekingalpha.com

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

August 5 at 10:31 AM | zacks.com

United Therapeutics Corporation 2026 Q2 - Results - Earnings Call Presentation

August 5 at 9:50 AM | seekingalpha.com

United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

August 5 at 8:46 AM | zacks.com

United Therapeutics: Q2 Earnings Snapshot

August 5 at 8:22 AM | aol.comA

United Therapeutics (NASDAQ:UTHR) surprises with Q2 CY2026 sales

August 5 at 8:22 AM | msn.com

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

August 5 at 6:30 AM | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, UTHR, MRNA, and INSM Company Descriptions

Insmed NASDAQ:INSM

$132.55 +33.53 (+33.86%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$133.00 +0.45 (+0.34%)

As of 07:43 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna NASDAQ:MRNA

$53.86 -2.40 (-4.27%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$54.80 +0.94 (+1.74%)

As of 07:43 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$70.85 +1.64 (+2.37%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$70.76 -0.09 (-0.13%)

As of 07:10 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

United Therapeutics NASDAQ:UTHR

$532.94 +13.93 (+2.68%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$543.50 +10.56 (+1.98%)

As of 07:26 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTCT, UTHR, MRNA, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTCT, UTHR, MRNA, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTCT, UTHR, MRNA, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, UTHR, MRNA, and INSM Company Descriptions

Insmed NASDAQ:INSM

Moderna NASDAQ:MRNA

PTC Therapeutics NASDAQ:PTCT

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTCT, UTHR, MRNA, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTCT, UTHR, MRNA, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTCT, UTHR, MRNA, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, UTHR, MRNA, and INSM Company Descriptions

Insmed NASDAQ:INSM

Moderna NASDAQ:MRNA

PTC Therapeutics NASDAQ:PTCT

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools